The Effect of Proprotein Convertase SubtilisinKexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population

Abstract EN

Background.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant effects on low-density lipoprotein (LDL) cholesterol and nonhigh density lipoprotein (HDL) cholesterol.

To date, there have been limited reports on the effect of PCSK9 inhibitors on remnant cholesterol.

Objectives.

Assess the effect of PCSK9 inhibitors on nonfasting remnant cholesterol in a real world population.

Identify whether pretreatment triglyceride levels are associated with PCSK9 inhibition success as indicated by changes in remnant cholesterol levels.

Methods.

Patients in our adult lipid clinic (n = 109) receiving PCSK9 inhibition for atherosclerotic cardiovascular disease or familial hypercholesterolemia who had available pre- and post-PCSK9 inhibition standard nonfasting lipid data were, retrospectively, selected for data analysis.

Remnant cholesterol was the difference between non-HDL and LDL cholesterol.

LDL cholesterol was measured directly and calculated from Friedewald and Martin/Hopkins methods.

Data were analyzed using repeated measures ANOVA and multivariable linear regression for differential effects on remnant and LDL cholesterol based upon pretreatment nonfasting triglyceride levels.

Results.

Remnant cholesterol as well as total, LDL, non-HDL cholesterol, and triglycerides decreased significantly (P<0.001) after PCSK9 inhibition.

Patients with higher pretreatment triglyceride levels showed greater decrease in remnant cholesterol after PCSK9 inhibition (P<0.001) than those with lower pretreatment triglycerides.

Conclusions.

In patients receiving PCSK9 inhibitors, remnant cholesterol as determined from nonfasting blood was reduced in proportion to pretreatment triglycerides.